New and notable appointments at Inflazome, Datalex and Diaceutics

Appointments, Business | Thu 29 Nov | Author – Business & Finance
Dr Thomas Jung

Business & Finance highlights notable new appointments at Inflazome, Datalex and Diaceutics

Dr Thomas JungChief Medical Officer


Inflazome announced the appointment of Dr Thomas Jung M.D., Ph.D. as its Chief Medical Officer.

Dr Jung joins Inflazome’s senior management team to lead the clinical development of its potent and selective small-molecule inhibitors of the NLRP3 inflammasome. Dr Jung will oversee the company’s global operations related to the development of Inflazome’s lead and next-generation compounds across a range of therapeutic indications; and will work collaboratively with Dr Jeff Thompson, Inflazome’s Head of Clinical Operations and Joanna Tufnell, Head of Regulatory Affairs.

Dónal RooneyChief Financial Officer

Dónal Rooney


Datalex plc, provider of digital commerce solutions to global travel retailers, announced the appointment of Dónal Rooney as Chief Financial Officer (CFO), Company Secretary and as a Director of Datalex with effect from 5th December 2018. Dónal succeeds David Kennedy who will remain with Datalex through the year end and will work closely with Dónal to assist his transition.

Prior to joining Datalex, Dónal was Group CFO of Amaris Hospitality (2016-2018) where he played a lead role in a successful Private Equity exit process. Amaris Hospitality was a leading hotel investment and management group, 100% owned by the global Private Equity firm, Lone Star, which brought together 89 hotels located in the UK, Ireland and Continental Europe trading under prominent brands such as Hilton, Jurys Inn and Mercure. From 2012-2016, Dónal was CFO of NAMA (National Asset Management Agency) having previously worked as a  Senior Portfolio Manager at NAMA from 2010-2012. Dónal began his career and qualified as a Chartered Accountant with Arthur Andersen (1997-2002) and also worked with KPMG (2002-2010).

Damian Thornton, Chief Operating Officer

Damian Thornton


Diaceutics, the diagnostic commercialisation company helping to improve patient outcomes through better testing, today announces the appointment of Damian Thornton to the position of Chief Operating Officer (COO). Damian will be responsible for the organisation’s business operations and strategic planning.

Reporting directly to founder and CEO Peter Keeling, a key focus for Damian will be continuing, and building on, the company’s impressive growth. Diaceutics currently partners with 31 of the world’s top 35 pharmaceutical companies and leverages a database from over 2,500 laboratories in 27 countries. Additional expansion is planned for new markets in Asia and South America.

With more than 25 years of international experience in the pharmaceutical industry, Damian has a significant track record in helping life science companies build and scale. He has led teams and projects across the globe including in China, Japan, the UK, Spain, Singapore, France and Brazil. His specialist knowledge and understanding of the pharmaceutical sector will help Diaceutics ensure more seriously ill patients get properly tested and treated.

Prior to Diaceutics, Damian served as Vice President for Asia at CAI International where he was in charge of strategic planning, project performance and sales forecasting. He was also Global Managing Director at Azbil Telstar and was responsible for growing the life science and research sectors globally, as well as leading the services division’s mergers and acquisitions strategy.

Damian received his bachelor’s degree in Chemical Engineering from Queen’s University Belfast and is a Chartered Member of the Institution of Chemical Engineers.